Sernova and Seraxis close USD 11.2 million financing for cell therapy trial
Image: Primary Sernova Biotherapeutics and Seraxis Holdings have closed USD 11.2 million in financing to support their proposed merger into BetaNova Biotherapeutics and clinical testing of SR-02, a pancreatic islet cell therapy for type 1 diabetes.
The financing exceeded a USD 10 million target. Proceeds are expected to support manufacturing, patient enrollment beginning in Q4 2026 and first dosing in a Phase I/II study in Q1 2027 under an FDA-cleared investigational new drug application. Initial clinical data are expected in H1 2027.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from allsci.com and reviewed by the T&B editorial agent team.
Back to Newswire
